Hudson Bay Capital Management
LPCN icon

Hudson Bay Capital Management’s Lipocine LPCN Stock Holding History

Hudson Bay Capital Management’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,651
Closed -$17K – 551
2019
Q4 		$17K Buy
+2,651
New +$67.9K ﹤0.01% 409

Other funds holding LPCN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
CL
Choreo LLC Rockford, Illinois $8.15B AUM 20.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FPCG
Fort Pitt Capital Group Pittsburgh, Pennsylvania $3.55B AUM 34.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Hudson Bay Capital Management's LPCN Position: Q1 2020 in Review

Hudson Bay Capital Management sold out of Lipocine (LPCN) in Q1 2020, closing a stake of 2,651 shares — an estimated $17K sold.

Hudson Bay Capital Management first reported a position in LPCN in Q4 2019 and held it in 1 quarter. The position peaked at $17K in Q4 2019. 28 funds tracked by Wall St. Rank hold LPCN as of Q1 2020.

  • Hudson Bay Capital Management reported no remaining Lipocine position as of Q1 2020 after selling out during the quarter.
  • Hudson Bay Capital Management sold 2,651 Lipocine shares in Q1 2020, an estimated $17K.
  • Hudson Bay Capital Management first reported a position in Lipocine in Q4 2019 and held it in 1 quarter.
  • Hudson Bay Capital Management's Lipocine position peaked at $17K in Q4 2019.
  • 28 funds tracked by Wall St. Rank held Lipocine as of Q1 2020.

Based on Hudson Bay Capital Management's 13F filing for Q1 2020, filed 14 May 2020.